

Convenient dosing²




One 550 mg tablet 3 times a day with or without food²



Just 2 weeks of treatment, not continuous daily prescription medication²



Patients who experience recurrence can be retreated up to 2 times²



ICD-10 code for IBS-D ^{3†}	
K58.0	Irritable bowel syndrome with diarrhea

INDICATIONS

XIFAXAN[®] (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued.
- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
- Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
- In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
 - HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
 - IBS-D (≥2%): Nausea (3%), ALT increased (2%)

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.


IBS-D=irritable bowel syndrome with diarrhea

¹Based on aggregated total of all prescribers as of June 2022.

[†]The ICD-10 codes and all other patient-access-related information are provided for informational purposes only. It is the treating physician's responsibility to determine the proper diagnosis, treatment, and applicable ICD-10 code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

References: 1. IQVIA Xponent. October 2022. 2. XIFAXAN [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals. 3. ICD-10. Centers for Medicaid & Medicare Services. www.cms.gov/Medicare/Coding/ICD10. Accessed August 7, 2020.

Convenient dosing¹



One 550 mg tablet, twice daily—no dose adjustments or titrations needed¹

- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.



Can be taken **with or without food¹**




Can be continued for as long as **patient is at risk of recurrent OHE¹**



ICD-10 code for overt HE^{2*}

K76.82

Hepatic Encephalopathy.
Indicate lactulose history if applicable.



XIFAXAN earned AASLD/EASL's highest possible recommendation[†] (GRADE I,A,1) as an add-on therapy to lactulose to reduce the risk of OHE recurrence after a patient has a recurrence while on lactulose alone.³

INDICATIONS

XIFAXAN[®] (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION (continued)

- INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
- XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout and click [here](#) for full Prescribing Information.

OHE=overt hepatic encephalopathy; AASLD=American Association for the Study of Liver Diseases; EASL=European Association for the Study of the Liver
[†]See ICD-10 code disclaimer on front.

[†]Per the GRADE System for Evidence: Grade I=randomized, controlled trials; A=evidence is "high quality," and further research is very unlikely to change our confidence in the estimated effect; and 1=recommendation is "strong," with factors influencing strength of recommendation including the quality of evidence, presumed patient-important outcomes, and costs.

References: 1. XIFAXAN [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals. 2. ICD-10. Centers for Medicaid & Medicare Services. www.cms.gov/medicare/icd-10/2023-icd-10-cm. Accessed July 27, 2022. 3. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*. 2014;60(2):715-735.